Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 3Terminated 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 682Neoplasms 594Carcinoma, Non-Small-Cell Lung 293Colorectal Neoplasms 292Prostatic Neoplasms 284Lung Neoplasms 224Melanoma 161Multiple Myeloma 151Neoplasm Metastasis 146Pancreatic Neoplasms 143Head and Neck Neoplasms 143Ovarian Neoplasms 136Carcinoma, Hepatocellular 126Leukemia, Myeloid, Acute 123Colonic Neoplasms 114Brain Neoplasms 113Squamous Cell Carcinoma of Head and Neck 111Uterine Cervical Neoplasms 109Stomach Neoplasms 106Recurrence 101Lymphoma 101Glioblastoma 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 83Lymphoma, Non-Hodgkin 82Hematologic Neoplasms 80Urinary Bladder Neoplasms 78Lymphoma, Follicular 78Glioma 77Parkinson Disease 4, Autosomal Dominant Lewy Body 74Sarcoma 72

Interventions

talimogene laherparepvec 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Ductal × 1 year × Clear all
NCT02779855 2026-03-10

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
50 enrolled 12 charts
Breast

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡